EAS Helsinki 2021 Virtual: What made the news?

More Science News Dr. Benjamin N. Wadström and colleagues (Herlev and Gentofte Hospital, Herlev, Denmark) highlighted an association between remnant cholesterol and risk for peripheral artery disease (PAD). High remnant cholesterol is already recognised as a risk factor for ischaemic heart disease and ischaemic stroke (1,2); however, whether it is also implicated in PAD is […]
Share this:

Continue reading


Focus on triglycerides

Wednesday News from EAS Congress: Triglycerides are very much on the ‘up.’ Professor Peter Libby (Brigham & Women’s Hospital, Harvard Medical School, Boston, USA) discussed triglycerides at the Joint EAS/International Atherosclerosis Society session. Furthermore, triglyceride metabolism was also the focus of this year’s key note lecture by Professor Chris Packard (University of Glasgow, UK). Triglyceride […]
Share this:

Continue reading


Post-truth medicine: Death and Disability by Disinformation

Monday News from EAS Helsinki 2021: Anitschkow Lecture Professor Sir Rory Collins, University of Oxford, UK We live in the Information Age, with access to information 24/7. Yet, as Professor Sir Rory Collins reminded us in his Anitschkow lecture, not all information is valid. In other words, misinformation—fake news—is as much an issue in scientific […]
Share this:

Continue reading


The rise of cardiometabolic disease

News from EAS Helsinki 2021 Virtual: Not only are we living in a COVID-19 pandemic, but also an accelerating pandemic of cardiometabolic disease, requiring renewed focus. The third plenary session discussed options to address this escalation in cardiometabolic disease. Professor Juleen Zierath (Karolinska Institute, Stockholm, Sweden and University of Copenhagen, Denmark) discussed new insights into […]
Share this:

Continue reading


Highlights from Late Breaking Session 2

Wednesday News from EAS Helsinki 2021 Virtual:  The Clinical Late Breaking Session highlighted real-world experience of the use of lipid lowering therapy from the HEYMANS study with evolocumab, the DA VINCI Study in Central and Eastern European (CEE) countries and the German Apheresis Registry. Clinical trials are fundamental to establishing the efficacy and safety of […]
Share this:

Continue reading


FH Roundtable: Next steps after the Global Call to Action on FH

In January 2020 the Global FH Community published a Call to Action on Familial Hypercholesterolaemia (FH), highlighting gaps in screening and guideline-based care for FH, the most common inherited metabolic disorder (1). The report was authored by a panel of scientific experts, public health officials, advocacy leaders and individuals with FH from 40 countries. Despite […]
Share this:

Continue reading


What is the future of CVD management?

Tuesday News from EAS Helsinki 2021: The second of the plenary sessions focused on new approaches to the detection and management of atherosclerotic cardiovascular disease (ASCVD), harnessing genetics, imaging, and innovation in pharmaceutical design. Dr Mark Daly (Institute for Molecular Medicine Finland) discussed how collaborative approaches using the FinnGen Biobank offer the opportunity for new […]
Share this:

Continue reading


Residual Risk beyond LDL: What is relevant?

Monday News from EAS Helsinki 2021:  Low-density lipoprotein cholesterol (LDL-C) is indisputably causal for atherosclerotic cardiovascular disease (ASCVD) (1). However, despite intensive LDL-C lowering, as demonstrated in the PCSK9 inhibitor trials (2,3), ASCVD patients experience recurrent events, underlining the need to target other factors.  This joint European Society of Cardiology (ESC)/EAS session discussed critical contributors […]
Share this:

Continue reading


How does metabolism dysfunction drive inflammation in the vessels?

Monday News from EAS Helsinki 2021 Virtual The EAS Plenary sessions provide state-of-the-art reviews by leading experts.  Plenary 1 of EAS Helsinki 2021 was no exception.  Mechanistic insights discussed in this session are integral to understanding the unmet clinical need of residual cardiovascular risk. Professor Gerard Pasterkamp (University Medical Center Utrecht, the Netherlands) discussed new […]
Share this:

Continue reading


Welcome to EAS Helsinki 2021 – Virtual: New directions for the EAS

The EAS is evolving…. In his welcome address, EAS President Professor Kausik Ray (Imperial College, London, UK) overviewed the new direction for the Society. Beyond its established role in scientific research, education – expanding to a new Digital platform – and dissemination, the EAS is building on links to the community. The Familial Hypercholesterolaemia Studies […]
Share this:

Continue reading